All Blogs
May 27, 2024
Emerging Therapies for Retinal Vein Occlusion Treatment: What Lies Ahead?
Retinal vein occlusion is the second most prevalent retinal vascular disease after diabetic retinopathy. Without treatment, it often results in a gradual decline in vision, ultimately causing permanent blindness. It ranks among the leading causes of vision loss globally, and this visual impairment significantly imp...
Read More...
Nov 08, 2024
Cervical Cancer Treatment: Navigating the Changing Landscape
Over the past two decades, the majority of countries in the 7MM have experienced a decrease in cervical cancer cases. In the United States, incidence rates declined from the mid-1970s to the mid-2000s, partly attributed to increased screening efforts. Cervical cancer is most often diagnosed between the age...
Read More...
May 23, 2024
Laborie’s Enhanced Gastrointestinal Diagnostics; Carestream’s Image Suite MR 10 Software Launch; Implicity’s Heart Failure Algorithm FDA 510(k) Approval; AngioDynamics’ AlphaVac F1885 System CE Mark Approval; HeartBeam’s Artificial Intelligence Algorithm for Arrhythmias; Onward ARC-EX Nerve Stim Hit Pivotal Trial
Laborie Launched Solar Compact System and Solar Anorectal Manometry Catheter for Enhanced Gastrointestinal Diagnostics On May 20, 2024, Laborie Medical Technologies Corp., launched the Solar Compact System and Solar Anorectal Manometry Catheter, the first disposable HRAM catheter on the market. These devices sig...
Read More...
May 22, 2024
The Evolution and Impact of Surgical Cameras in Modern Medicine
In the fast-paced and precision-driven world of modern medicine, surgical cameras have emerged as a transformative technology. Among the myriad of technological advancements, surgical cameras stand out as a transformative innovation. These devices have revolutionized the way surgeons perform operations, offering un...
Read More...
May 21, 2024
Amgen’s IMDELLTRA FDA Approval; J&J’s Proteologix Acquisition; Bristol Myers Squibb’s BREYANZI FDA Approval; AbbVie and Gilgamesh Pharmaceuticals’ Agreement; Eisai’s LEQEMBI FDA Fast Track Status
IMDELLTRA Receives FDA Approval as the First T-Cell Engager Therapy for Advanced Small Cell Lung Cancer Amgen has reported that the FDA has approved IMDELLTRA™ (tarlatamab-dlle) for treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression following pl...
Read More...
May 20, 2024
Atopic Dermatitis Treatment: Rich Portfolio of Therapeutic Options Shaping the Future
Atopic dermatitis is common worldwide, and people of all ages, from newborns to adults 65 and older, live with this condition. The World Health Organization (WHO) Global Burden of Diseases initiative estimates more than 230 million people globally have atopic dermatitis and that skin diseases are the fourth leading...
Read More...
May 17, 2024
GSK and iTeos Alliance Boosts Belrestotug Prospects in TIGIT Space
iTeos shares jump by 40%. GSK and iTeos collaboration for Belrestotug looks like a worthy wait. Hopes to ward off the negative sentiments around the volatile TIGIT space? In the ever-evolving landscape of cancer immunotherapy, the pursuit of effective treatment strategies continues to drive innovation and invest...
Read More...
May 16, 2024
Siemens Healthineers USD 314 Million Investment; Samsung Medison’s Sonio Acquisition; Leo Cancer Care’s Upright Technology Clearance; OrthoXel’s Vertex Hip Fracture Nail FDA 510 (k) Clearance; SPR Therapeutics’ PNS Pain Relief Device Positive Data; Valneva’s Chikungunya Vaccine Positive Pivotal Phase III Data
Siemens Healthineers Invested USD 314 Million in New MRI Manufacturing Plant On May 15, 2024, Siemens Healthineers announced that it had invested USD 314 million in a new MRI manufacturing plant in the UK. The facility in Oxford, England, which Siemens anticipates opening in 2026, will develop technology to redu...
Read More...
Jun 06, 2025
The Rise of Sleep Tech Devices: Unlocking Better Sleep
In today’s fast-paced world, achieving quality rest can be challenging—this is where sleep tech devices are making a difference. Leveraging innovative sleep trackers for detailed insights and smart tech for better sleep, the latest sleep technology products help users monitor and enhance their sleep patterns. From ...
Read More...
May 14, 2024
Takeda and AC Immune’s Alzheimer’s Deal; Eli Lilly’s Donanemab FDA Review; Bristol Myers Squibb’s Phase III CheckMate -73L Trial Result; Regeneron Pharmaceuticals’ Dupixent sBLA; Excision BioTherapeutics’ EBT-101 Phase I/II Trial Results
Takeda and AC Immune Ink Exclusive Deal for Active Immunotherapy in Alzheimer’s, Focusing on Amyloid Beta Takeda and AC Immune SA have unveiled an exclusive global option and licensing pact concerning AC Immune’s active immunotherapies directed at harmful variants of amyloid beta (Abeta), notably ACI-24.060, int...
Read More...